Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Breast Cancer Research and Treatment|July 9, 2017
Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancerZhaomei Mu, Chun Wang, Zhong Ye, et al.
The Prostate|January 16, 2008
Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivoZhaomei Mu, Paul Hachem, Harvey Hensley, et al.
International Journal of Radiation Oncology, Biology, Physics|July 20, 2007
Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivoRadka Stoyanova, Paul Hachem, Harvey Hensley, et al.
International Journal of Cancer|October 21, 2010
PKA knockdown enhances cell killing in response to radiation and androgen deprivationHarvey H Hensley, Jean-Michel Hannoun-Levi, Paul Hachem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor CellsCarmela Paolillo, Zhaomei Mu, Giovanna Rossi, et al.
Breast Cancer Research and Treatment|August 13, 2015
The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based studyYinzhi Lai, Zhong Ye, Jesse M Civan, et al.
International Journal of Molecular Sciences|October 6, 2016
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast CancerZhaomei Mu, Naoual Benali-Furet, Georges Uzan, et al.
Ebiomedicine|February 13, 2016
Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma CellsMizue Terai, Zhaomei Mu, David J Eschelman, et al.
Breast Cancer Research and Treatment|November 18, 2015
Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancerZhaomei Mu, Chun Wang, Zhong Ye, et al.
The Oncologist|February 9, 2017
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on AbirateroneJianqing Lin, Sheel A Patel, Ashwin R Sama, et al.
Pageof 3